Entries by surrozen

Surrozen Announces Publication of Two Abstracts Providing Evidence for Liver-Targeted Tissue Regeneration

— Abstracts originally accepted for 2020 Digestive Disease Week Conference – to be published online  — SOUTH SAN FRANCISCO, Calif., May 4, 2020 — Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, announced today that two abstracts were published on the 2020 Digestive Disease Week (DDW) site. These abstracts were […]

Surrozen Scientific Founder Roel Nusse, PhD Receives Prestigious Canada Gairdner International Award for Biomedical Research

—Award recognizes Dr. Nusse’s seminal contributions to elucidating the mechanism and role of Wnt signaling— SOUTH SAN FRANCISCO, Calif., April 6, 2020 — Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, today announced that one of its scientific founders, Dr. Roel Nusse, received the 2020 Canada Gairdner International Award for […]

Surrozen Announces Publication of Antibody Platform Technology in Cell Chemical Biology

— Novel approach to creating Wnt-mimetics establishes proof-of-concept for targeted regenerative antibodies — SOUTH SAN FRANCISCO, Calif., March 30, 2020 — Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, today announced a peer-reviewed publication describing its novel platform for generation of potent and selective Wnt-mimetics. The article, “Development of Potent, […]

Surrozen to Present at Cowen and Company 40th Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., March 2, 2020 – Surrozen, Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies to repair a broad range of tissues, today announced that President & Chief Executive Officer, Craig Parker, will present at the Cowen and Company 40th Annual Health Care Conference in Boston, Massachusetts. The presentation will begin at 10:30 a.m. […]

Surrozen Appoints Dr. Trudy Vanhove as Chief Medical Officer

SOUTH SAN FRANCISCO, Calif., April 11, 2019 (GLOBE NEWSWIRE) — Surrozen Inc., a company discovering and developing novel antibodies for regenerative medicine with a focus on specific control of the Wnt signaling pathway, today announced the appointment of Trudy Vanhove, MD, PhD, MBA, as Chief Medical Officer. An experienced biopharmaceutical executive, Dr. Vanhove brings to […]

Surrozen Raises $50 Million in Series B Financing to Advance Regenerative Antibody Platforms and Liver Disease Candidates

— Anna Berkenblit, MD, appointed to Surrozen Board of Directors — SAN FRANCISCO, March 14, 2019 (GLOBE NEWSWIRE) — Surrozen Inc., a company discovering and developing novel antibodies for regenerative medicine with a focus on specific control of the Wnt signaling pathway, today announced the successful completion of a $50 million Series B financing. The […]

Surrozen Strengthens Leadership Team with Addition of New CEO and Scientific Co-founder

SAN FRANCISCO, April 4, 2018 /PRNewswire/ — Surrozen, a preclinical-stage company advancing drug candidates that promote the repair and regeneration of human tissues, today announced two appointments to expand its leadership team.  Craig Parker, a biotech industry veteran recently of Jazz Pharmaceuticals, has been appointed CEO, and Hans Clevers, M.D., Ph.D., professor of molecular genetics at the Hubrecht Institute, […]

Surrozen Launches Into Regenerative Medicine With $33 Million in Series A Financing Led by The Column Group

— Founded on key discoveries from Stanford University that enable selective Wnt pathway activation, Surrozen advances novel regenerative medicines with broad applications for human health — SOUTH SAN FRANCISCO, Calif., Feb. 15, 2017 /PRNewswire/ — Surrozen Inc., a newly formed biopharmaceutical company focused on discovering and developing drugs that promote the repair and regeneration of human tissues, has […]